Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR-NCI-EORTC International Conference 2023

Allorion Therapeutics Inc, a clinical-stage biotechnology company that develops novel small molecule drugs for cancer and autoimmune diseases, today announced that two abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, Massachusetts.

Abstracts accepted for poster presentation:

Title: CDK2 inhibition demonstrates synthetic lethality in SCLC through apoptotic induction

Poster #: A022 Presenter: Nathan Schomer Date and Time: Thursday, October 12; 12:30 p.m. – 4:00 p.m.

Title: The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers

Poster #: B173 Presenter: Yaoyu Chen Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.